Clinical Trials Browser

Phase 2 × Not yet recruiting × Genitourinary × Clear all

NCT07574541 2026-06-05

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Phase 2 Not yet recruiting

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

NCT07625527 2026-06-04

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT07627464 2026-06-04

ALTER-UC-011

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07623460 2026-06-03

ZENITH

Phase 2 Not yet recruiting

mCRPC (Metastatic Castration-resistant Prostate Cancer)

NCT07623642 2026-06-03

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Phase 2 Not yet recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07624201 2026-06-03

Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

Phase 2 Not yet recruiting

Muscle-Invasive Bladder Cancer (MIBC)

NCT07608718 2026-05-27

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07602101 2026-05-22

Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07593040 2026-05-20

Moonlanding

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07592910 2026-05-18

MOMENT

Phase 2 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07593079 2026-05-18

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07516366 2026-05-15

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07578025 2026-05-11

Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Phase 2 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07578519 2026-05-11

Radiation Treatment of the Prostate That is Specially Adjusted for Each Person

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07576335 2026-05-08

ROBOPREP

Phase 2 Not yet recruiting

Erectile Dysfunction, Prostatic Neoplasms, Urinary Incontinence

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Phase 2 Not yet recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT07568756 2026-05-06

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07568236 2026-05-05

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07037004 2026-05-04

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07223385 2026-05-04

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

Phase 2 Not yet recruiting

Disease, Prostatic Neoplasms

NCT07226713 2026-05-04

POSTPONE

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07043608 2026-05-01

ZAMBONI

Phase 2 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT07414992 2026-05-01

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07224009 2026-04-24

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07549256 2026-04-24

ProCan

Phase 2 Not yet recruiting

Marijuana Abuse, Prostatic Neoplasms

NCT07550517 2026-04-24

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Phase 2 Not yet recruiting

High-Risk Localized Prostate Cancer

NCT07535905 2026-04-17

REVIVE

Phase 2 Not yet recruiting

Hypogonadism, Prostatic Neoplasms

NCT07518979 2026-04-09

MH-Penile-002

Phase 2 Not yet recruiting

Penile Neoplasms

NCT07354594 2026-04-08

ARREST

Phase 2 Not yet recruiting

Prostate Cancer Metastatic Castration-Resistant

NCT07515651 2026-04-07

MIDAS-SBRT

Phase 2 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07516210 2026-04-07

ART-Hypo

Phase 2 Not yet recruiting

GastrointestinalGenitourinaryGynecologic

Uterine Cervical Neoplasms, Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

NCT07512076 2026-04-06

A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07494435 2026-03-27

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07497919 2026-03-27

A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer

Phase 2 Not yet recruiting

Penile Neoplasms

NCT07470840 2026-03-24

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07490210 2026-03-24

OMPC-RPM

Phase 2 Not yet recruiting

Oligometastatic Prostate Cancer

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Phase 2 Not yet recruiting

Muscle Invasive Bladder Cancer (MIBC)

NCT07476677 2026-03-17

ANDARP

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07457164 2026-03-12

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

Phase 2 Not yet recruiting

Urogenital Diseases, Prostatic Diseases

NCT07466498 2026-03-12

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07077083 2026-03-11

CAIX PET/CT

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07441837 2026-03-11

TeLuNa

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07460206 2026-03-10

PRELUDE

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07460245 2026-03-10

AVESEC

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT07415135 2026-02-17

Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07387510 2026-02-04

DGPR1008-04

Phase 2 Not yet recruiting

Prostate Cancer Patients Undergoing Radical Prostatectomy

NCT06836726 2026-01-28

EVO

Phase 2 Not yet recruiting

Castration Resistant Prostate Cancer

NCT07364071 2026-01-27

SENTRY

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07346404 2026-01-16

RUBIKID

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, Neovascularization, Pathologic